- Home
- VSTD vs OGEN Comparison
VSTD vs OGEN Comparison
Compare VSTD & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VSTD | OGEN |
|---|---|---|
| Founded | 2016 | 1996 |
| Country | United States | United States |
| Employees | 259 | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1M | 3.6M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | VSTD | OGEN |
|---|---|---|
| Price | $0.29 | $0.53 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 68.6K | ★ 266.6K |
| Earning Date | 05-04-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.20 | $0.11 |
| 52 Week High | $2.20 | $9.16 |
Technical Indicators
Market Signals| Indicator | VSTD | OGEN |
|---|---|---|
| Relative Strength Index (RSI) | 43.30 | 28.59 |
| Support Level | $0.21 | N/A |
| Resistance Level | $0.37 | $1.06 |
| Average True Range (ATR) | 0.02 | 0.09 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 0.00 | 0.85 |
Price Performance
Historical ComparisonAbout VSTD Vestand Inc.
Vestand Inc is a California-based fast-growing restaurant operator expanding into the real estate investment and development sector. It is a PropTech company engaged in AI-driven real estate investment and security token offerings (STOs). It provides services such as Property Acquisition, Property Development, Financial Management, and Property Management.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.